Acrivon Therapeutics, Inc. (“Acrivon” or the ”Company”) (NASDAQ: ACRV) is a clinical stage biopharmaceutical company developing precision oncology medicines that it matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing the Company’s proprietary proteomics-based patient responder identification platform. Acrivon’s approach is designed to overcome the limitations of genomics-based patient selection methods. The Company does this by using its proprietary precision medicine platform, Acrivon Predictive Precision Proteomics (“AP3”), to develop its pipeline of oncology drug candidates. The Company’s AP3 platform enables the creation of drug-specific proprietary OncoSignature companion diagnostics that are used to identify the patients most likely to benefit from its drug candidates. The Company is currently advancing its lead candidate, ACR-368, a selective small molecule inhibitor targeting CHK1 and CHK2 with sub single-digit nM and single-digit nM potency, respectively, in a potentially registrational Phase 2 trial across multiple tumor types, which the Company’s AP3 platform predicts will have a high proportion of patient responders based on OncoSignature-predicted sensitivity to ACR-368. Acrivon has received clearance from the U.S. Food and Drug Administration (“FDA”), for an Investigational New Drug application to advance ACR-368 in Phase 2 single arm clinical trials conducted under the FDA program known as the master protocol, which was developed to help expedite drug development in multiple tumor types for drugs with an established recommended Phase 2 dose within the same overall trial structure. In addition to ACR-368, the Company is also advancing its preclinical pipeline programs targeting WEE1 and PKMYT1, respectively.